Brugada syndrome drugs to avoid
Brugada syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Brugada syndrome drugs to avoid On the Web |
American Roentgen Ray Society Images of Brugada syndrome drugs to avoid |
Risk calculators and risk factors for Brugada syndrome drugs to avoid |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The following drugs should be avoided in patients with Brugada syndrome. [1][2]
Generic name | Brand name® | Class / Clinical use | References | Recommendation |
Ajmaline | e.g. Gilurytmal® - more brand names here - |
Antiarrhythmic Agent (1A: Na-blocker) / Arrhythmias | Brugada 1997 Rolf 2003 Wolpert 2005 Bébarová 2005 |
Class I |
Flecainide | e.g. Tambocor® - more brand names here - |
Antiarrhythmic Agent (1C: Na-blocker) / Arrhythmias | Krishnan 1998 Brugada 2000 Gasparini 2003 Meregalli 2006 Stokoe 2007 |
Class I |
Pilsicainide | e.g. Sunrhythm® - more brand names here - |
Antiarrhythmic Agent (1C: Na-blocker) / Arrhythmias | Takenaka 1999 Fujiki 1999 Takagi 2002 Kimura 2004 |
Class I |
Procainamide | e.g. Procan® Pronestyl® - more brand names here - |
Antiarrhythmic Agent (1A: Na-blocker) / Arrhythmias | Miyazaki 1996 Brugada 1997 Joshi 2007 Villemaire 1992 |
Class I |
Propafenone | e.g. Rythmol® - more brand names here - |
Antiarrhythmic Agent (1C: Na-blocker) / Arrhythmias | Matana 2000 Akdemir 2002 Hasdemir 2006 Shan 2008 Stark 1996 |
Class IIa |
Recommendation: Class I: convincing evidence/opinion; Class IIa: evidence/opinion less clear; Class IIb: conflicting evidence/opinion; Class III: very little evidence.